Elizabeth Holmes

Elizabeth Anne Holmes (born February 3, 1984) is an American entrepreneur who founded Theranos in 2003 and served as its chief executive officer. The company claimed that its technology could perform a broad range of blood tests using very small samples collected through a finger prick. These claims attracted substantial investment and made Holmes a prominent figure in Silicon Valley, before investigations exposed discrepancies between the company’s representations and its laboratory capabilities. (en.wikipedia.org)

Holmes’s career became the subject of investigative reporting, regulatory proceedings, and a federal criminal prosecution. On January 3, 2022, a jury convicted her of one count of conspiracy to commit wire fraud and three counts of wire fraud involving investors; it acquitted her on four patient-related counts and did not reach verdicts on three other investor-related counts. On November 18, 2022, she was sentenced to 135 months in federal prison. Her biography encompasses Theranos’s formation, financing, commercial expansion, and collapse, together with the legal proceedings and nonfiction and dramatized accounts that followed. (justice.gov)

Early life and education

Elizabeth Anne Holmes was born on February 3, 1984, in Washington, D.C., to Christian Holmes IV and Noel Holmes. Her mother worked as a congressional committee staffer; her father’s career included government service and international development work. The family moved to Houston, Texas, during her childhood. Holmes attended St. John’s School, a private school in Houston’s River Oaks neighborhood, and graduated in 2002, before leaving Texas to attend university. (biography.com)

Holmes began studying Mandarin Chinese while growing up in Houston. Her parents arranged private tutoring, and she subsequently attended Stanford’s summer Mandarin program while still in high school. Her adolescent interests also included computer programming and entrepreneurship. She later described starting a business that sold C++ compilers to Chinese universities. This account of an early commercial venture appeared in biographical reporting; it was separate from the biomedical research she undertook after entering college. (en.wikipedia.org)

In 2002, Holmes enrolled at Stanford University, where she studied chemical engineering and worked as a student researcher and laboratory assistant in the School of Engineering. One of her teachers was Channing Robertson, whose introductory chemical-engineering course she took during her first year. Robertson later recalled, in a deposition reported by ABC News, that Holmes approached him in approximately the fall of 2002 to ask whether she could work in his laboratory. Their association therefore began during her undergraduate studies, before he became involved with her company. (en.wikipedia.org)

After her freshman year, Holmes spent the summer of 2003 working at the Genome Institute of Singapore, where her laboratory experience included research connected with severe acute respiratory syndrome. On returning to Stanford, she pursued an idea for a wearable patch intended to combine testing with drug delivery and filed a patent application in 2003. The patch was a proposed invention, not an established medical product. Robertson became a mentor and subsequently a supporter of her business venture; a 2012 Stanford engineering profile identified Holmes as his former undergraduate student and recorded his role as a Theranos director. (en.wikipedia.org)

Holmes left Stanford in March 2004, during her second academic year, without completing a degree, to concentrate on her company. Her departure followed the beginning of her entrepreneurial work rather than preceding it: Theranos originated in 2003, while she was still enrolled. Robertson’s involvement continued beyond her university education, linking her undergraduate laboratory experience with the company’s early development. (newyorker.com)

Establishment of Theranos

Holmes founded Real-Time Cures in Palo Alto, California, in 2003, while she was a nineteen-year-old student at Stanford University. She subsequently renamed the business Theranos, combining “therapy” and “diagnosis.” As founder and chief executive, she directed a venture initially concerned with integrating medical monitoring and treatment, rather than simply providing laboratory tests. The company’s establishment preceded her departure from Stanford in 2004, when she left her degree unfinished to work on the business full-time. (en.wikipedia.org)

The original proposal was a wearable patch that would combine several functions: monitor substances in a patient’s bodily fluids, administer medication, and adjust delivery in response to the measurements. Holmes’s patent application, titled Medical device for analyte monitoring and drug delivery, described devices capable of detecting an analyte—a substance being measured—and optionally releasing a therapeutic agent. Its priority history begins on September 11, 2003; the subsequent nonprovisional application was published in May 2005 and granted as a U.S. patent in November 2007. These dates distinguish the initial filing from the later patent grant. The document described a proposed invention, not evidence that an integrated diagnostic and drug-delivery patch had been demonstrated in clinical use. (patents.google.com)

During the company’s early development, its focus shifted away from the patch toward blood testing using very small samples. This changed the intended product: instead of a wearable system that both monitored a patient and delivered medication, Theranos pursued equipment for analyzing blood collected separately. The commercial proposition became making diagnostic information available with less blood and less burdensome collection than conventional blood draws. These were development objectives and, subsequently, marketing claims; the founding concept itself did not establish the breadth or reliability of tests that the company could perform. (biography.com)

Channing Robertson, Holmes’s professor of chemical engineering at Stanford, provided early academic and organizational support. He backed her decision to pursue the venture and became an early board member and adviser. His involvement connected the new company to an established university researcher, but his role was distinct from Holmes’s executive responsibility for building and managing the business. Robertson continued his association with Theranos beyond its founding period, serving in technical advisory roles. (en.wikipedia.org)

Venture capitalist Tim Draper supplied an important early financial commitment: a $1 million investment. Draper was the father of Holmes’s childhood friend Jesse Draper, so their connection preceded the company. His backing supplied startup capital while Theranos was still developing its proposed technology, rather than purchasing an already established diagnostic service. The early venture thus brought together Holmes’s leadership, Robertson’s academic support, and Draper’s investment—three different forms of participation that should not be conflated with independent clinical validation of the proposed products. (en.wikipedia.org)

Blood-testing claims and laboratory capabilities

Holmes promoted Theranos’s blood-testing technology as capable of performing the tests offered by conventional laboratories using blood collected through a finger prick rather than a larger venous draw. She also claimed that its proprietary analyzers would deliver faster, cheaper, and more accurate results. The advertised system combined distinct functions: finger-prick collection obtained the specimen; the “nanotainer” held it; and an analyzer performed the laboratory measurements. The nanotainer was therefore a collection container, not itself a testing instrument. According to the court record, finger-prick specimens collected in nanotainers were tested either on Theranos’s Edison instrument or on modified commercial equipment. Later proprietary instruments, including the miniLab, remained in development; the Edison was the only Theranos-developed analyzer used for patient testing. (justice.gov)

The breadth of testing advertised substantially exceeded the proprietary platform’s demonstrated clinical capabilities. In its March 2018 civil complaint, the Securities and Exchange Commission alleged that investor materials described comprehensive testing from finger-stick samples, although Theranos’s proprietary sample-processing unit performed only 12 of the tests offered to patients. The complaint further alleged that third-party analyzers performed the majority of the company’s testing, contrary to representations that Theranos manufactured all its analyzers. These were civil allegations; the subsequent appellate account of the criminal trial likewise recorded that only 12 assays were ever run on the Edison and that general-chemistry tests were performed on third-party machines, some modified and others unmodified. Offering a test through Theranos’s laboratory was thus not equivalent to performing it on Theranos’s proprietary technology. (sec.gov)

Reliability problems concerned both the Edison and laboratory procedures. The court record describes repeated failures of quality-control checks, in which samples with known concentrations were tested to determine whether instruments returned acceptable results. A late-2015 inspection by the Centers for Medicare & Medicaid Services identified deficiencies involving tests performed on both Edison instruments and modified commercial analyzers. Separately, FDA inspectors documented inadequate complaint investigation and missing documentation of software-validation activities and corrective actions. One complaint concerned nanotainers whose opacity made it difficult to inspect specimens for clotting. These observations concerned the collection and quality-management systems as well as the instruments producing measurements. (cdn.ca9.uscourts.gov)

Claims of independent validation also exceeded the supporting evidence. The Justice Department’s account of the trial stated that Holmes supplied investors with reports bearing pharmaceutical-company logos that falsely suggested those companies had comprehensively evaluated and endorsed the technology. The same account reported that Theranos ultimately voided all patient results generated by its proprietary analyzer after determining that every test presented a possible patient impact. That retrospective decision addressed the reliability of the reported results; it did not establish that every individual result had necessarily been incorrect. (justice.gov)

The failure of Theranos’s broad representations does not establish that small-volume blood testing is inherently impossible. The FDA’s 2015 review of Theranos’s HSV-1 IgG antibody assay addressed a specific test and specimen-processing workflow, rather than validating the company’s entire advertised menu. Its collection instructions specified two nanotainer tubes containing 80 microliters each, followed by refrigerated transport, centrifugation, and laboratory analysis. The review included studies of reproducibility, specimen types, and agreement with a reference method. Such assay-specific evidence distinguished a defined small-volume application from the much broader claim that a single proprietary platform could replace conventional laboratory testing across a comprehensive range of tests. (accessdata.fda.gov)

Financing, ownership, and corporate leadership

Theranos relied on private investment to finance its development: Holmes had raised approximately $6 million by December 2004, and the company had obtained more than $92 million in venture capital by the end of 2010. Its investors eventually included Rupert Murdoch and investment vehicles associated with the Walton, DeVos, and Cox families. According to the Securities and Exchange Commission’s March 2018 civil complaint, Theranos raised more than $700 million in two financing rounds from late 2013 through 2015. These were investment proceeds, not sales revenue. The SEC reported that the company generated only a little more than $100,000 in operating revenue in 2014, despite representations that revenue that year would exceed $100 million. (en.wikipedia.org)

Holmes combined substantial equity ownership with voting rights disproportionate to her economic stake. The SEC complaint describes an early-2014 restructuring that introduced Class B shares, reserved for Holmes, carrying 100 times the voting power of ordinary shares. After the restructuring, she owned just over half the outstanding shares but controlled more than 99 percent of shareholder votes. This arrangement allowed further fundraising without a corresponding loss of her voting control. Her March 2018 SEC settlement subsequently required conversion of the super-voting shares into Class A shares and relinquishment of majority voting control; she settled without admitting or denying the allegations. (sec.gov)

Holmes served as chief executive and board chair, while Ramesh “Sunny” Balwani was president and chief operating officer from September 2009 to May 2016 and also served as a director. The SEC described a division of responsibilities: Holmes concentrated on device innovation, board relations, and strategic partnerships; Balwani oversaw software development, personnel, and operations. They nevertheless made company decisions together. Balwani’s involvement also had a financing dimension: in 2009, when Theranos was nearing exhaustion of its funds, Holmes turned to him to guarantee a credit line. (sec.gov)

The board brought together senior figures from government, the military, and business. Former secretary of state George Shultz joined in 2011; subsequent directors included fellow former secretary of state Henry Kissinger, former defense secretary William Perry, former senators Sam Nunn and Bill Frist, retired military officers James Mattis and Gary Roughead, and business executives Richard Kovacevich and Riley Bechtel. These directorships were distinct from investment participation or employment in the laboratory: a place on the board did not itself establish that a person had financed the company or performed technical validation of its testing methods. (en.wikipedia.org)

Theranos announced a reorganization of its corporate governance in October 2015. Its five-person governing board comprised Holmes, Balwani, Bechtel, Mattis, and lawyer David Boies, previously an outside legal adviser. Shultz and Kissinger moved to a separate board of counselors rather than retaining governing-board seats. A medical board was also being formalized, with founding members including Frist, former Centers for Disease Control and Prevention director William Foege, orthopedic surgeon David Helfet, and Prostate Cancer Foundation chief executive Jonathan Simons. The resulting structure distinguished governing directors from counselors and medical advisers, rather than placing all prominent affiliates in a single leadership body. (beckershospitalreview.com)

Commercial expansion and public prominence

On September 9, 2013, Theranos and Walgreens announced a retail partnership, with the first Theranos Wellness Center opening that month inside a Walgreens pharmacy on University Avenue in Palo Alto, California. The announcement presented a nationwide expansion as the eventual objective, not an already established service. It advertised clinician-directed blood testing from very small samples, rapid results, and prices no higher than half the corresponding Medicare reimbursement rates; these were the companies’ promotional claims, rather than independent assessments of performance. The Walgreens locations served as blood-collection sites, with samples transported to Theranos laboratories for analysis. The operating network remained concentrated in California and Arizona: by the partnership’s termination in June 2016, Walgreens had 40 Theranos centers in Arizona, having already halted services at its Palo Alto location that January. (corporate.walgreens.com)

The separate Safeway project did not produce a comparable public testing network. As reported by The Wall Street Journal in November 2015, Safeway had spent approximately $350 million building clinics in more than 800 supermarkets in anticipation of offering Theranos testing. The projected service never began in those stores, and the companies were negotiating to dissolve their arrangement. The expenditure concerned Safeway’s clinic construction and preparation, not $350 million in realized Theranos testing revenue. The distinction between these two partnerships was therefore substantial: Walgreens introduced an operating, geographically limited collection service, whereas Safeway prepared a much larger physical infrastructure without launching the intended retail tests. (liu.edu)

During this expansion, private investors valued Theranos at approximately $9 billion. Holmes’s ownership was commonly reported as roughly half the company, supporting Forbes’s contemporary estimate of her personal wealth at $4.5 billion. In May 2015, she headed the magazine’s inaugural ranking of America’s richest self-made women. That figure represented an estimate attached to her equity ownership in a privately held business: Theranos shares were not publicly traded, and the estimate did not mean that Holmes had received $4.5 billion in salary, dividends, or proceeds from selling shares. The corporate valuation, investment capital, operating revenue, and estimated personal fortune were distinct financial measures. (forbes.com)

Magazine coverage made Holmes widely recognizable beyond the investment community. Roger Parloff’s Fortune cover profile appeared in June 2014. Ken Auletta’s “Blood, Simpler,” published online by The New Yorker on December 8, 2014, described her retail ambitions and a TEDMED appearance. His account explicitly compared her black suit and black turtleneck with Steve Jobs’s clothing. Such comparisons formed part of her contemporary public presentation within Silicon Valley, rather than evidence about the testing system’s capabilities. In 2015, Time included her in its annual list of 100 influential people, accompanied by a profile written by Henry Kissinger, who was also a Theranos director. (fortune.com)

Holmes also appeared at prominent business and policy gatherings. On September 29, 2015, she joined Alibaba executive chairman Jack Ma and former U.S. president Bill Clinton at the Clinton Global Initiative’s closing plenary for a discussion of equality and opportunity. She spoke at Vanity Fair’s New Establishment Summit that October. These appearances placed her alongside established corporate and political figures while the company’s proposed national retail expansion remained largely prospective. (upi.com)

Investigative reporting and employee disclosures

John Carreyrou’s investigation for The Wall Street Journal examined the gap between Theranos’s public descriptions of its blood-testing technology and its laboratory operations. Published online on October 15, 2015, his first major report, “Hot Startup Theranos Has Struggled With Its Blood-Test Technology,” drew on former employees’ accounts and internal emails. It reported that, although Theranos offered more than 240 tests, a former senior employee said its proprietary Edison instrument routinely performed only 15 as of December 2014. Most testing, the article reported, used conventional analyzers purchased from manufacturers such as Siemens. These were attributed findings of the newspaper’s investigation, not regulatory determinations at the time of publication. (abcnews.com)

The reporting also questioned accuracy and proficiency testing: whether external checks adequately represented the instruments used for patients. One employee’s complaint to regulators alleged that Theranos had withheld results raising doubts about Edison’s precision. Theranos disputed the reported limit of 15 tests, declined to disclose its current number, and invoked trade secrets when answering some laboratory questions. Its lawyer David Boies nevertheless acknowledged that Edison did not perform every test offered; he described comprehensive testing on the proprietary instrument as a future goal. General counsel Heather King said website wording about small sample volumes had been changed for marketing accuracy. (yoannbazin.wordpress.com)

Former laboratory associate Erika Cheung contributed observations from inside the company and separately contacted the Centers for Medicare & Medicaid Services (CMS). In her subsequent sworn testimony, she described recurring quality-control failures, discrepancies between Edison and conventional instruments, and manual removal of outlying data points without a defined protocol. She said she raised concerns internally, including with president Ramesh “Sunny” Balwani, before leaving and speaking to a journalist. Her regulatory disclosure was distinct from her participation in Carreyrou’s reporting. During her 2021 testimony, she qualified her recollection of its timing: she recalled initially contacting CMS by telephone and submitting a formal complaint months later, possibly in September 2015. (holmes.courtdaemon.com)

Tyler Shultz, a former Theranos employee and grandson of director George Shultz, was another source. According to reporting published in November 2016, he had questioned inconsistent results and the exclusion of outlying values from validation reports, raised concerns with Holmes, and complained anonymously to New York officials in 2014. His identity was therefore disclosed publicly after the initial investigation, rather than in its first article. Shultz later described legal pressure concerning confidentiality and efforts to obtain the identities of other sources; ABC News’s account drew partly on his recorded deposition. Theranos declined to comment on KQED’s November 2016 account of the disclosures. (kqed.org)

Holmes and Theranos publicly rejected the investigation. On October 15, Holmes appeared on CNBC’s Mad Money with Jim Cramer to defend the company and characterize the criticism as resistance to change. Theranos’s contemporaneous statement disputed the reporting’s scientific and factual basis, challenged former employees’ knowledge, and said it had supplied more than 1,000 pages of rebuttal materials. Holmes also addressed the allegations at the Journal’s technology conference on October 21; the company published a further point-by-point response on October 22. (inc.com)

Subsequent disclosures supported central elements of the investigation without making every original allegation an adjudicated fact. By May 2016, Theranos had voided tens of thousands of test results. The SEC’s March 2018 civil complaint subsequently alleged that the proprietary analyzer performed only 12 patient tests and that Theranos had concealed its extensive reliance on third-party equipment. That later allegation concerned the period examined by the SEC; it was not the same numerical claim as the newspaper’s report about December 2014. (abcnews.com)

Regulatory intervention and the company’s closure

The Food and Drug Administration (FDA) inspected Theranos’s Newark, California, facility between August 25 and September 16, 2015. Its Form FDA 483 recorded that the company was shipping an uncleared capillary-tube nanotainer collection device between states while identifying it as an exempt Class I device. Inspectors also documented inadequate complaint-handling procedures and failures to record investigations and corrective actions. One uninvestigated complaint concerned containers whose opacity made it difficult to inspect blood specimens for clotting. These were inspection observations, not a blanket determination about every Theranos product. Separately, the FDA’s July 2, 2015, clearance covered a specific test for antibodies to herpes simplex virus type 1, including specified specimen-collection components and uses; it did not authorize Theranos’s entire advertised blood-testing menu or establish the performance of its platform across other tests. (fda.gov)

Laboratory oversight proceeded separately through the Centers for Medicare & Medicaid Services (CMS), under the Clinical Laboratory Improvement Amendments (CLIA). A recertification and complaint survey concluded on December 23, 2015, after inspectors received additional information from Theranos. In a January 25, 2016, letter, CMS notified the company of deficiencies and a finding of immediate jeopardy to patient health and safety. CMS rejected the laboratory’s February response as insufficient evidence of correction and proposed sanctions on March 18. Further submissions during March and April also failed to demonstrate that the laboratory had corrected its deficiencies and removed the immediate jeopardy. (wsj.com)

On July 7, 2016, CMS issued its sanctions notice. It restricted hematology testing effective July 15, imposed a civil monetary penalty of $10,000 per day beginning July 12 until specified corrective or limiting conditions were met, and ordered revocation of the Newark laboratory’s CLIA certificate effective September 5, subject to postponement through a timely administrative appeal. The notice explained that revocation would prohibit the laboratory’s owners and operators, including its director, from owning, operating, or directing a laboratory for at least two years—the restriction affecting Holmes as an owner. It also terminated eligibility for Medicare and Medicaid payments on specified schedules. These measures concerned laboratory certification and operation, rather than Holmes’s ability to manage a company generally. (en.wikisource.org)

The company’s withdrawal of test results overlapped with these proceedings. By May 2016, Theranos had invalidated all results produced by its Edison instruments in 2014 and 2015 and issued corrected reports to doctors and patients; the withdrawals did not encompass every test performed by the company during those years. On June 12, Walgreens terminated its relationship with Theranos and announced the closure of all 40 Theranos Wellness Centers in its Arizona stores, ending its retail provision of Theranos testing services. (time.com)

On October 5, 2016, Holmes announced that Theranos would close its clinical laboratories and blood-collection centers, eliminating approximately 340 positions in Arizona, California, and Pennsylvania. The remaining business would concentrate on developing the miniLab testing platform rather than providing patient-testing services. An agreement announced on April 17, 2017, resolved the outstanding CMS proceedings: Theranos agreed not to operate a clinical laboratory for two years, CMS withdrew the certificate revocations, and the company’s monetary penalty was reduced to $30,000. The settlement therefore altered the sanctions while preserving a period outside the laboratory-services business. (statnews.com)

Holmes stepped down as chief executive on June 15, 2018, and was succeeded by general counsel David Taylor; she initially remained board chair. In September, Theranos moved to dissolve after an unsuccessful sale process involving approaches to more than 80 prospective buyers. Taylor’s shareholder communication described approximately $5 million in remaining cash and at least $60 million owed to unsecured creditors. The proposed winding-up arrangements would transfer patents to secured lender Fortress Investment Group and preserve the remaining cash for other creditors, with no distribution to shareholders. (investing.com)

SEC civil proceedings and settlement

On March 14, 2018, the U.S. Securities and Exchange Commission (SEC) brought civil fraud proceedings against Theranos, Elizabeth Holmes, and former company president Ramesh “Sunny” Balwani. The agency alleged that they had raised more than $700 million from investors through false or misleading statements about the company’s technology, business, and financial performance. Its complaints invoked the antifraud provisions of federal securities law, including Section 17(a) of the Securities Act of 1933 and Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5. Theranos and Holmes agreed to settlements when the proceedings were announced; Balwani did not join those settlements. These were civil allegations, not criminal convictions. (sec.gov)

The technology allegations concerned what investors were told through presentations, demonstrations, and media coverage. According to the SEC, investors were led to believe that Theranos’s proprietary analyzer could perform comprehensive blood testing using finger-prick samples, although it performed only a limited range of tests and the company used third-party commercial instruments for most patient testing. The agency also alleged that Holmes and Balwani falsely represented that Theranos equipment had been deployed by the Department of Defense on battlefields in Afghanistan and aboard medical-evacuation helicopters. On financial performance, the SEC contrasted representations of more than $100 million in revenue for 2014 with actual operating revenue of little more than $100,000. (sec.gov)

The complaint against Holmes and Theranos also described alleged misrepresentations about commercial relationships. Investor materials included reports bearing pharmaceutical-company logos that, the SEC alleged, suggested independent endorsements even though Theranos employees had written two of the reports. The complaint further alleged that revenue forecasts implied substantial business from pharmaceutical services, hospitals, and physicians’ offices, although those lines generated no revenue in 2014. It distinguished forecasts from purported historical results: in August 2015, Holmes allegedly supplied one prospective investor with financial information showing $108 million in 2014 net revenue. These allegations addressed the information used to solicit investment, rather than merely whether Theranos ultimately met ambitious business targets. (sec.gov)

The final judgment entered on March 27, 2018, required Holmes to pay a $500,000 civil penalty and return 18,897,137 Theranos Class B shares—approximately 18.9 million shares—to the company within 14 days. It also required conversion of her remaining Class B shares into Class A shares within 28 days, relinquishing her majority voting control. Holmes was barred for ten years from serving as an officer or director of a public company covered by the judgment’s federal registration or reporting provisions; the restriction was not a general prohibition on employment or entrepreneurship. The judgment also permanently enjoined violations of the specified securities antifraud provisions. (sec.gov)

Holmes settled without admitting or denying the complaint’s allegations, apart from jurisdictional matters and a limited provision treating the allegations as admitted for specified bankruptcy-discharge purposes. She waived findings of fact and conclusions of law, so the consent judgment did not constitute a trial determination of the allegations. The civil penalty, share surrender, and governance restrictions were separate from the federal criminal prosecution announced in June 2018. That prosecution required proof beyond a reasonable doubt; the SEC settlement neither established criminal guilt nor resolved the criminal charges. (sec.gov)

Federal criminal prosecution and verdict

On June 14, 2018, a federal grand jury in the Northern District of California indicted Holmes and Theranos president Ramesh “Sunny” Balwani on two counts of conspiracy to commit wire fraud and nine substantive wire-fraud counts. The charges alleged two distinct schemes: one to obtain investors’ money through misleading representations about Theranos, and another to defraud doctors and patients through representations about its testing services. Superseding charging documents followed on July 14 and July 28, 2020. The operative third superseding indictment contained twelve counts: an investor-related conspiracy, six investor-related wire-fraud counts, a patient-related conspiracy, and four patient-related wire-fraud counts. These were criminal allegations, separate from the earlier SEC civil proceedings. (justice.gov)

On March 20, 2020, Judge Edward J. Davila ordered separate trials, with Holmes to be tried first. Her trial proceeded in San Jose in September 2021 and lasted fifteen weeks; Balwani’s followed in 2022. Prosecutors presented testimony from investors, former employees, business partners, and patients, alongside financial documents, company reports, communications, and a recording of Holmes’s December 2013 investor call. The prosecution’s case addressed not merely whether Theranos had failed commercially, but whether Holmes knowingly used material misrepresentations to obtain money. (govinfo.gov)

Witnesses supplied specific contrasts between the company’s representations and its operations. Former employees described failures of laboratory quality controls and the use of commercial analyzers for tests that investors believed were performed on proprietary equipment. General James Mattis testified that Theranos devices had not been deployed on the battlefield or installed on military medical-evacuation aircraft. Pharmaceutical-company representatives testified that their companies had neither independently validated the technology nor authorized their logos’ appearance on favorable Theranos reports. Investors explained why purported external validation and the company’s technological capabilities mattered to their investment decisions. These accounts, together with the documentary evidence, supported prosecutors’ argument that the discrepancies reflected knowing deception rather than unsuccessful development alone. (cdn.ca9.uscourts.gov)

Holmes testified in her own defense over seven trial days. Her defense contested the inference of fraudulent intent, maintaining that she believed in the technology and relied on information supplied by scientific and operational personnel. In reviewing the trial record, her lawyers emphasized evidence of efforts to investigate and correct laboratory problems, and testimony that laboratory director Adam Rosendorff had never been instructed by Holmes to report inaccurate results. Holmes acknowledged adding pharmaceutical-company logos to reports, but testified that she intended to identify companies with which Theranos had worked, not falsely imply that they had authored the reports. She also attributed nondisclosure of modifications to commercial analyzers to concerns about protecting trade secrets. These explanations were presented as her testimony and defense position, rather than independently established descriptions of her intent. (cdn.ca9.uscourts.gov)

On January 3, 2022, the jury returned a mixed verdict. It convicted Holmes of the investor-related conspiracy, Count 1, and three investor-related wire-fraud charges, Counts 6–8, involving transfers totaling more than $140 million. It acquitted her of the patient-related conspiracy, Count 2, and three patient-related wire-fraud charges, Counts 10–12. Jurors could not agree on three remaining investor charges, Counts 3–5. A fourth patient-related wire-fraud charge, Count 9, had already been dismissed during trial and therefore was not an acquittal: the government acknowledged that confusion between two blood tests had caused it to omit the relevant test from its bill of particulars. The eleven counts submitted to the jury thus produced four convictions, four acquittals, and three unresolved counts. (justice.gov)

Sentencing, imprisonment, and subsequent review

On November 18, 2022, Judge Edward J. Davila of the United States District Court for the Northern District of California sentenced Holmes to 135 months—11 years and three months—in federal prison, followed by three years of supervised release. The terms imposed on her four counts of conviction were concurrent, rather than consecutive. No criminal fine was assessed; the amount of restitution was reserved for a subsequent determination. These were the judicially imposed penalties, distinct from the Bureau of Prisons’ later calculations of time to be served and projected release dates, which can reflect statutory credits without constituting a resentencing. (govinfo.gov)

On May 16, 2023, Davila ordered Holmes and Ramesh “Sunny” Balwani to pay $452,047,268 in restitution to victims of the fraud. Their liability was joint and several: both were responsible for the shared obligation, rather than each owing a separate $452 million award. The order applied the Mandatory Victims Restitution Act and addressed losses arising from the fraudulent scheme, including losses associated with Walgreens and Safeway, rather than only the transfers underlying Holmes’s three substantive wire-fraud convictions. Restitution was compensation owed to victims, not a criminal fine payable as punishment to the government. (govinfo.gov)

Holmes sought to remain free while appealing. On April 10, 2023, Davila denied her application, finding that, although she had demonstrated she was unlikely to flee or endanger others, her appeal did not satisfy the statutory requirements for release pending review. In particular, the court concluded that the evidentiary issues she raised were not likely to require reversal or a new trial on all the convictions supporting imprisonment. After further proceedings concerning her surrender date, Holmes entered federal custody on May 30, 2023, at the Federal Prison Camp in Bryan, Texas. (govinfo.gov)

The Ninth Circuit heard argument on June 11, 2024, and on February 24, 2025, affirmed the convictions, sentences, and restitution order in the consolidated appeals involving Holmes and Balwani. Judge Jacqueline H. Nguyen wrote the opinion. The court found that some employee testimony crossed into expert-opinion territory but that any resulting error was harmless; it also rejected Holmes’s challenges concerning regulatory evidence, limits on cross-examination, and the exclusion of portions of Balwani’s SEC testimony. An amended opinion filed on December 22, 2025, preserved the affirmance. On restitution, it explained that the calculation should account for any residual value of investors’ shares, but concluded that the omission was harmless because the factual findings established losses equal to the investments. The accompanying order denied Balwani’s petitions for panel and en banc rehearing. (cdn.ca9.uscourts.gov)

Separately, on December 29, 2023, the Department of Health and Human Services’ inspector general notified Holmes of a 90-year exclusion from Medicare, Medicaid, and all other federal health-care programs under section 1128(a)(3) of the Social Security Act. This administrative exclusion concerned program participation, not imprisonment, corporate officeholding under the SEC settlement, or laboratory certification. An administrative law judge upheld it on April 25, 2025; the Departmental Appeals Board affirmed that decision on January 16, 2026. The board held that the investor-fraud convictions had the required connection to the delivery of health-care items or services. It sustained the duration based on four aggravating factors: financial losses, conduct lasting at least one year, significant adverse effects on individuals, and a sentence including incarceration. It found no established regulatory mitigating factor warranting a reduction. (hhs.gov)

Books, documentaries, and dramatizations

John Carreyrou’s Bad Blood: Secrets and Lies in a Silicon Valley Startup, published by Knopf in May 2018, expanded his investigation of Theranos into a book-length nonfiction account. It was distinct from the newspaper articles he had begun publishing in The Wall Street Journal in 2015: the book reconstructed the company’s development, its dealings with investors and commercial partners, and the experiences of employees who questioned its laboratory practices. It also described the reporting process and efforts to prevent disclosures. Its subject was therefore both Theranos’s operations and the investigative journalism that brought discrepancies between its public claims and laboratory capabilities to wider attention. The original edition preceded Holmes’s criminal trial rather than providing an account of its findings. (penguinrandomhouse.com)

Alex Gibney directed and produced the documentary The Inventor: Out for Blood in Silicon Valley, which premiered on HBO on March 18, 2019. Produced by HBO Documentary Films and Jigsaw Productions, it combined interviews with archival material and footage from within Theranos. Interview subjects included Carreyrou and former employees Erika Cheung and Tyler Shultz. Unlike a scripted biographical film, it presented recorded appearances by Holmes herself, alongside other participants’ accounts and Gibney’s editorial framing. The documentary examined the contrast between the company’s public presentation and its underlying technology, including the authority Holmes acquired through prominent supporters and comparisons with Steve Jobs. Like the original Bad Blood, it appeared before the criminal trial. (en.wikipedia.org)

ABC News’s investigative podcast The Dropout launched in January 2019. Correspondent Rebecca Jarvis hosted the series, working with producers Taylor Dunn and Victoria Thompson. Its reporting drew on a multiyear investigation and included interviews with former employees, investors, and patients, as well as previously unaired recordings of deposition testimony by Holmes and others. This audio format distinguished contemporaneous recordings from the journalists’ narration and retrospective interviews. Beginning on August 31, 2021, the follow-up series The Dropout: Elizabeth Holmes on Trial covered the federal proceedings, explaining witness testimony and evidence as the trial unfolded rather than merely repeating the original rise-and-fall narrative. (en.wikipedia.org)

Hulu adapted the podcast into the eight-episode scripted limited series The Dropout, which began streaming on March 3, 2022. Elizabeth Meriwether created the series and served as showrunner; Amanda Seyfried portrayed Holmes, while Naveen Andrews played Ramesh “Sunny” Balwani. Jarvis, Dunn, and Thompson also served as executive producers, connecting the adaptation to its journalistic source. The production nevertheless used actors, scripted dialogue, and reconstructed private interactions rather than presenting a documentary record. Meriwether described its approach as an interpretation of Holmes as a character, and production finished before the criminal trial concluded. Its portrayals of conversations, motives, and relationships are therefore dramatic representations, not independent documentary evidence or findings by the court. (etonline.com)

References

1. Elizabeth Holmes: Biography, Theranos Founder, Entrepreneurbiography.com
2. Elizabeth Holmes' 11-year prison sentence begins Tuesday in Bryan, Texashoustonchronicle.com
3. Elizabeth Holmes - Wikipediaen.wikipedia.org
4. Ex-Theranos employees describe culture of secrecy at Elizabeth Holmes' startup: ‘The Dropout’ podcast ep. 1abcnews.com
5. The not-so-retiring retirement of Channing Robertsonengineering.stanford.edu
6. One Woman’s Drive to Revolutionize Medical Testingnewyorker.com
7. Theranosen.wikipedia.org
8. US20050100937A1 - Medical device for analyte monitoring and drug delivery - Google Patentspatents.google.com
9. Channing Robertsonen.wikipedia.org
10. Bad Blood by John Carreyroueverand.com
11. Elizabeth Holmes Sentenced To More Than 11 Years For Defrauding Theranos Investors Of Hundreds Of Millionsjustice.gov
12. United States v. Holmes, amended opinion, December 22, 2025cdn.ca9.uscourts.gov
13. Elizabeth Holmes and Theranos, Inc.: SEC Complaintsec.gov
14. Theranos, Inc., Newark, CA: FDA Form 483, issued September 16, 2015fda.gov
15. 510(k) Substantial Equivalence Determination: Theranos HSV-1 IgG Assayaccessdata.fda.gov
16. Theranos, CEO Holmes, and Former President Balwani Charged With Massive Fraudsec.gov
17. Theranos Founder and Former Chief Operating Officer Charged In Alleged Wire Fraud Schemesjustice.gov
18. Theranos Selects Walgreens as a Long-Term Partner Through Which to Offer Its New Clinical Laboratory Servicecorporate.walgreens.com
19. Elizabeth Holmesforbes.com
20. USA v. Holmescdn.ca9.uscourts.gov
21. This CEO's out for bloodfortune.com
22. President Clinton speaks with Elizabeth Holmes and Jack Ma (2015 CGI Annual Meeting)youtube.com
23. Hot Startup Theranos Has Struggled With Its Blood-Test Technologyyoannbazin.wordpress.com
24. Ex-Theranos CEO Elizabeth Holmes says 'I don't know' 600-plus times in never-before-broadcast deposition tapesabcnews.com
25. Erika Cheung — Direct/Cross (Continued) - Day 7 - Federal Criminal Trialholmes.courtdaemon.com
26. Theranos Whistleblower Was George Shultz' Grandson: WSJkqed.org
27. Theranos Posts Fact Sheetazbio.org
28. 510(k) Premarket Notification: Theranos Herpes Simplex Virus-1 IgG Assayaccessdata.fda.gov
29. 510(k) Substantial Equivalence Determinationaccessdata.fda.gov
30. CMS Imposition of Sanctions on Theranos, Inc.wsj.com
31. Walgreen Co. v. Theranos, Inc.: Report and Recommendationscases.justia.com
32. Walgreens terminates relationship with Theranos; closes 40 centers in Arizonafinance.yahoo.com
33. Theranos to shut labs, lay off hundreds as mission shiftsstatnews.com
34. Theranos Settles with CMSgenengnews.com
35. Embattled blood-testing firm Theranos to dissolve - WSJfinance.yahoo.com
36. Elizabeth Holmes, et al. and Ramesh "Sunny" Balwanisec.gov
37. Final Judgment as to Defendant Elizabeth Anne Holmessec.gov
38. U.S. v. Elizabeth Holmes, et al. — Case overviewjustice.gov
39. U.S. v. Elizabeth Holmes, et al.justice.gov
40. 18-258 — USA v. Holmes et al.: Order Re Severance of Trialsgovinfo.gov
41. Theranos Founder Elizabeth Holmes Found Guilty Of Investor Fraudjustice.gov
42. United States v. Holmes — Appellant’s Opening Briefcdn.ca9.uscourts.gov
43. Elizabeth Holmes confronts feds’ fraud accusations in third day of testimonycourthousenews.com
44. United States v. Holmes: Order Denying Motion for Release Pending Appealgovinfo.gov
45. BOP: First Step Act, Frequently Asked Questionsbop.gov
46. BOP: Sentence Computationsbop.gov
47. United States v. Holmes: Order on Restitutiongovinfo.gov
48. Elizabeth A. Holmes, DAB No. 3222 (2026)hhs.gov
49. Bad Blood by John Carreyroupenguinrandomhouse.com
50. Bad Bloodpenguinrandomhousesecondaryeducation.com
51. I'm John Carreyrou, author of Bad Blood, the book about the Theranos scandal. Ask me anything.reddit.com
52. The Inventor: Out for Blood in Silicon Valleyen.wikipedia.org
53. The Inventor: Out for Blood in Silicon Valleyrottentomatoes.com
54. Theranos and Silicon Valley get bloodied in Alex Gibney's 'The Inventor'sfchronicle.com
55. The Dropout (podcast)en.wikipedia.org
56. Podcast: 'The Dropout: Elizabeth Holmes on Trial'www-cdn.abcnews.com
57. How to Watch 'The Dropout' Online: Streaming Details, Episodes, and Moreetonline.com
58. The Dropoutpress.hulu.com
59. Elizabeth Meriwetherpress.hulu.com